{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:27:52Z","timestamp":1791912472881,"version":"4.3.4"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018748","name":"Argenx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>This case describes successful response to efgartigimod in the treatment of myasthenic crisis secondary to paraneoplastic disease, and in the perioperative setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An elderly female presented with speech difficulties, cessation of eating and 10kg weight loss over 4 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Examination revealed ptosis, dysarthria, nasal speech, and weakness in limbs and neck flexors. Single fiber electromyography demonstrated abnormal jitter response in the orbicularis oculi muscle. Nicotinic acetylcholine receptor antibodies were detected in serum. The patient was diagnosed with very-late-onset myasthenia gravis (MG) in a myasthenic crisis and later required intubation and admission to intensive care but was unresponsive to plasma exchange. Paraneoplastic disease was suspected and computed tomography revealed a bladder mass. Efgartigimod 10 mg\/kg was administered intravenously to stabilize her condition before surgery. The patient\u2019s Myasthenia Gravis Activities of Daily Living (MG-ADL) score decreased from 19 to 14 after the first dose and she subsequently underwent surgical removal of the bladder tumor without complication. Her condition continued to improve post-operatively with completion of the first treatment cycle. Four cycles of efgartigimod over 10 months resulted in an MG-ADL score of 3.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Efgartigimod may be a novel treatment for perioperative management of MG, myasthenic crisis, and paraneoplastic MG. Further study is warranted.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1524200","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T06:41:55Z","timestamp":1738046515000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Case report: Successful perioperative intervention with efgartigimod in a patient in myasthenic crisis"],"prefix":"10.3389","volume":"16","author":[{"given":"Shahar","family":"Shelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2008.02242.x","article-title":"Paraneoplastic myasthenia gravis: immunological and clinical aspects","volume":"15","author":"Skeie","year":"2008","journal-title":"Eur J Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2004.040378","article-title":"Paraneoplastic syndromes: when to suspect, how to confirm, and how to manage","volume":"75","author":"Rees","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s12883-021-02311-8","article-title":"Myasthenia gravis associated with renal cell carcinoma: a paraneoplastic syndrome or just a coincidence","volume":"21","author":"Zheng","year":"2021","journal-title":"BMC Neurol"},{"key":"B4","article-title":"Anesthesia for patients with myasthenia gravis","volume-title":"StatPearls","author":"Neuman","year":"2022"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e19781","DOI":"10.1097\/MD.0000000000019781","article-title":"Myasthenic crisis and late deep vein thrombosis following thymectomy in a patient with myasthenia gravis: A case report","volume":"99","author":"Lin","year":"2020","journal-title":"Med (Baltimore)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjae.2021.07.001","article-title":"Perioperative management of myasthenia gravis","volume":"21","author":"Daum","year":"2021","journal-title":"BJA Educ"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.21037\/apm-21-695","article-title":"Severe complications and management of a patient with myasthenia gravis undergoing anterior cervical spinal surgery: a case report","volume":"11","author":"Li","year":"2022","journal-title":"Ann Palliat Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0180433","article-title":"Outcomes after major surgery in patients with myasthenia gravis: A nationwide matched cohort study","volume":"12","author":"Chang","year":"2017","journal-title":"PloS One"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2022.01.023","article-title":"The effects of elective abdominal surgery on protein turnover: A meta-analysis of stable isotope techniques to investigate postoperative catabolism","volume":"41","author":"Jaconelli","year":"2022","journal-title":"Clin Nutr"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10071537","article-title":"Drugs that induce or cause deterioration of myasthenia gravis: An update","volume":"10","author":"Sheikh","year":"2021","journal-title":"J Clin Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"B13","unstructured":"VYVGART\u00ae prescribing information\n          \n          \n          2024"},{"key":"B14","unstructured":"VYVGART\u00ae summary of product characteristics\n          \n          \n          2024"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15872","article-title":"Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis","volume":"30","author":"Sacc\u00e0","year":"2023","journal-title":"Eur J Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1524200\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T06:41:59Z","timestamp":1738046519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1524200\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":15,"alternative-id":["10.3389\/fimmu.2025.1524200"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1524200","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"article-number":"1524200"}}